View Single Post
Old 08-09-2017, 09:57 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
for those with leptomeningeal metastases

Send to
Breast Care (Basel). 2017 Jul;12(3):165-167. doi: 10.1159/000464400. Epub 2017 Jun 26.
Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer.
Laakmann E1, Witzel I1, Müller V1.
Author information

Abstract
BACKGROUND:
Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine.
CASE REPORTS:
The first case represents a 53-year-old woman with LM of breast cancer. A neurological response was achieved shortly after the start of the multimodal treatment including intrathecal liposomal cytarabine. The response duration reached 79 days. The second case represents a 48-year-old woman with LM of breast cancer treated with intrathecal liposomal cytarabine as a part of a multimodal treatment approach. A neurological response was achieved in the first 2 weeks of treatment and is still lasting after 18 months.
CONCLUSION:
These cases suggest that a rapid response to a prompt start of treatment with intrathecal liposomal cytarabine in patients with LM of breast cancer is feasible. In 1 case an extremely long progression-free survival (18+ months) was achieved. The cases support the efficacy of liposomal cytarabine in the management of LM in breast cancer patients as a part of a multimodal treatment approach and underline the need for further investigations in this specific cohort.
KEYWORDS:
Breast cancer; Leptomeningeal metastasis; Liposomal cytarabine
PMID: 28785184 PMCID: PMC5527186 [Available on 2018-07-01] DOI: 10.1159/000464400
Share on FacebookShare on Twitter
Lani is offline   Reply With Quote